Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.

Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at the 2025 ASCO Meeting.

No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.

Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Erika Hamilton is the director of breast and gynecologic cancer research at Sarah Cannon Research Institute in Nashville, Tennessee.

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Safety Profiles to Look Out For in New Breast Cancer Treatments

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Those who took dexamethasone reported higher levels of satisfaction than patients on placebo.

Olanzapine/Triplet Cuts Chemo-Induced Nausea, Vomiting in Breast Cancer

Panitumumab plus FOLFIRINOX or mFOLFOX6 failed to yield meaningful responses in liver-limited, RAS/BRAF wild-type unresectable mCRC.

Panitumumab-Based Chemo Falls Short in Liver-Limited mCRC

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Conference Archive

ASCO Annual Meeting

Sintilimab with neoadjuvant chemoradiotherapy enhanced pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.

Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC

ASCO Gastrointestinal Cancers Symposium (ASCO GI)

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.

Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC

ASCO Genitourinary Cancers Symposium (ASCO GU)

Frontline treatment with enfortumab vedotin/pembrolizumab is associated with the highest healthcare costs for patients with locally advanced or metastatic urothelial carcinoma.

Newer Urothelial Cancer Drugs Are Effective But Pricey

ASCO Quality Care Symposium

Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.

Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC

American Association for Cancer Research Annual Meeting (AACR)

Although frontline treatment with lenvatinib plus pembrolizumab improved ORR and PFS, it did not improve OS when compared with placebo in patients with head and neck squamous cell carcinoma.

Lenvatinib Plus Pembrolizumab Generates Responses But No OS Benefit in HNSCC

American Society for Therapeutic Radiology and Oncology (ASTRO) 

The haplotype is more common in patients achieving a complete hematologic response, indicating its potential as a treatment response biomarker.

Ropeginterferon Alfa-2b Response Improves With NFKB1 Haplotype in PV and ET

American Society of Hematology Annual Meeting & Exposition 

Community urology practices have routinely used darolutamide in both doublet and triplet regimens to treat metastatic hormone-sensitive prostate cancer.

Doublet and Triplet Darolutamide Regimens Routinely Used in mHSPC

American Urological Association Annual Meeting

Dexamethasone sparing in cisplatin-based chemotherapy did not impair global health status, although it did worsen nausea and appetite loss.

Dexamethasone Sparing with Cisplatin-Based Chemotherapy Does Not Significantly Impact QoL

Annual Meeting on Supportive Care in Cancer

The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.

New Metastatic Melanoma Therapies Create Hope for Patients, Key Role for Oncology Nurses

Annual NCONN Conference

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer

Annual School of Nursing Oncology

A study recently found that patients treated for breast cancer may experience decisional regret about their fertility choices.

Many Breast Cancer Survivors Experience Decisional Regret About Fertility

Cancer Survivorship Symposium

Assisted reproductive techniques may be safe for patients with BRCA-mutated breast cancer, according to an ESMO study.

Assisted Reproductive Techniques May Be Safe in BRCA-Mutated Breast Cancer

ESMO Breast Cancer Congress

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed. 

Sacituzumab Tirumotecan Shows Promise in Pretreated Gynecologic Cancer

ESMO Congress

Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer.

Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer

ESMO World Congress On Gastrointestinal Cancer 

Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said. 

Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL

European Hematology Association Congress

Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.

Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC

IASLC World Conference on Lung Cancer

At the international congress on the Future of Breast Cancer West, Hope S. Rugo highlighted the predictive value of residual cancer burden scoring in ongoing research efforts to tailor triple-negative breast cancer treatments. 

Prognostic Link Between pCR and Survival Outcomes May Be Key to Personalized Medicine Efforts in Early-Stage TNBC

International Congress on the Future of Breast Cancer

Resistance training and walking can be beneficial for patients with multiple myeloma. 

Ambulation Improves Frailty Scores in Patients With Multiple Myeloma

International Myeloma Workshop

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.

Finley-Oliver Weighs in on Caring for Heavily Pretreated Patients With High-Risk Multiple Myeloma

JADPRO

Acupuncture Use in BC Predicted by Social Determinants of Health

ONS Annual Congress

Stephanie Russell, DNP, AGNP-C, highlights the importance of gender-neutral language in the oncology environment. 

How To Use Inclusive Language When Caring for Transgender Persons With Cancer

ONS Bridge

Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space. 

Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection 

PER® Chemotherapy Foundation Symposium (CFS)

Caregivers of patients with GBM have an increased time burden and can affect the quality of life of the caregiver and, potentially, the patient with cancer.

Intervene Early to Support Caregivers of Patients With Glioblastoma

Palliative Care In Oncology Symposium

In the modern era, the number of patients with diffuse large B-cell lymphoma who will derive benefit from autologous stem cell transplantation is small, according to Jeremy S. Abramson, MD, MMSc.

Evolution of DLBCL Treatment Options Render ASCT Unsuitable for Many Patients

Pan Pacific Lymphoma Conference 

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

Ribociclib Combo May Provide Benefit to Certain Breast Cancer Subtypes

San Antonio Breast Cancer Symposium

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer

Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

Patients with hematologic malignancies who received Orca-T improved survival rates compared with PTCy in those receiving myeloablative conditioning, according to findings from a retrospective analysis.

Conferences

Latest Conference Coverage